Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Recce secures A$85m R&D backing as Phase 3 nears Recce Pharmaceuticals (ASX: RCE) hit a one-week high after landing an A$85 million Advanced Overseas Finding from AusIndustry. This ruling is among the largest reported under Australia’s R&D Tax Incentive program. The finding means Recce's international clinical programs now qualify for the government's 43.5% tax rebate…

ByUjjwal MaheshwariDecember 17, 2025

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Cynata Therapeutics (ASX: CYP) has completed patient enrollment in its Phase 2 clinical trial of a stem cell treatment called CYP-001 for acute graft versus host disease (aGvHD), a potentially life-threatening complication that affects up to 50 per cent of bone marrow transplant patients. With 65 participants now enrolled across clinical centres in the US,…

ByUjjwal MaheshwariDecember 16, 2025

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Neurizon Therapeutics (ASX: NUZ) just hit a major milestone. The FDA has cleared its lead drug NUZ-001 to enter the HEALEY ALS Platform Trial at Massachusetts General Hospital, with patients now enrolling for this Phase 2/3 study in Q4 2025. This follows the FDA lifting its clinical hold back in October 2025. For investors, the…

ByUjjwal MaheshwariDecember 12, 2025

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Race Oncology’s (ASX: RAC) latest capital raise sends a strong signal. The company secured A$3.2 million from sophisticated investors at $2.83 per share, a 6% premium to its last close. For a small-cap biotech, that’s unusual; most need to offer discounts to attract funding. This premium placement shows investors are confident about the upcoming HARNESS-1…

ByUjjwal MaheshwariDecember 10, 2025

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Imugene wins FDA support, funding risk remains Imugene (ASX: IMU) received a major regulatory boost this week after the US Food and Drug Administration confirmed support to advance its cancer therapy Azer-Cel into a pivotal Phase 3 study. Written minutes from a November 21 Type C meeting showed clear alignment on trial design, patient population,…

ByUjjwal MaheshwariDecember 9, 2025

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

On Monday December 22, the ASX quarterly rebalance will be effective. Stocks will be promoted into new indices, while others will be demoted. It is important to note from the outset the June and December rebalances only involve the ASX 50, ASX 100 and ASX 200 indices whilst the March and September rebalances also involve…

ByNick SundichDecember 9, 2025

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

$100bn biotechs like Vertex Pharmaceuticals (NDQ:VRTX) typically get to their position through 'blockbuster drugs' with periods of market exclusivity, which eventually come to an end and cause revenues to fall as cheaper biosimilars come onto the market. The average biotech is facing a loss of revenue of 38%. Of course, some are higher (i.e. Amgen…

ByNick SundichOctober 23, 2025

Rejecting a takeover offer: Here are 6 ASX stocks that did and how it ended for them

Rejecting a takeover offer is a bold step for an ASX company to take. It is turning down sweet quick cash for its shareholders and management. The argument most commonly made to reject them is that any offers are opportunistic and do not appropriately value the company - indeed, those very words are commonly used. The board…

ByNick SundichOctober 14, 2025

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

The dream run Pfizer had during the pandemic was not going to last forever. But while certain companies that derived a windfall during the pandemic (one example being Sonic (ASX:SHL)) had decent businesses pre-COVID and began to 'normalise' post-pandemic, Pfizer has continued to decline (shares have dropped another 12% in 2025). What are the Best ASX…

ByNick SundichOctober 13, 2025

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Biotech company Mesoblast (ASX:MSB) is the ultimate definition of a rollercoaster company. As of October 7, 2025, it is capped at $3.2bn, which makes it the third largest 'biotech' behind CSL and Telix (note: we're just talking biotechs, not healthcare stocks more broadly - although if you include all healthcare stocks, MSB still makes the…

ByNick SundichOctober 9, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Recce Pharmaceuticals (ASX: RCE) Secures A$85M R&D Backing: Is It a Buy Before Phase 3 Results?

Cynata Therapeutics Completes Phase 2 Enrollment- Buy Before June or Wait for the Data?

Neurizon (ASX:NUZ) Clears FDA Hurdle for ALS Trial- Speculative Buy at 75% Off Highs?

Race Oncology Raises $3.2m at 6% Premium: Is RAC Still a Buy After 87% Rally?

Imugene (ASX: IMU) Gets FDA Green Light for Phase 3: Time to Buy the Dip?

Here are 6 stocks that got promoted in the ASX quarterly rebalance, and 6 that got demoted

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer

Rejecting a takeover offer: Here are 6 ASX stocks that did and how it ended for them

Pfizer (NYSE:PFE) shares are still declining post-pandemic! Does the company have a future?

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here